Sino BiopharmaceuticalSBMFF -4.96%62 FCF Margin % is 32.96% as of Dec. 2025, which is 107% above its 10-year median of 15.90. GuruFocus rates SBMFF with a GF Score™ of 62/100 and a GF Value™ of $0.68 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 960 Biotechnology companies, Sino Biopharmaceutical ranks better than 91.04% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBMFF vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (SBMFF) has a FCF Margin % of 32.96% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sino Biopharmaceutical and its competitors. This is 107% above median its historical median of 15.90. Over the past decade, Sino Biopharmaceutical's FCF Margin % has ranged from 12.93 to 23.92. According to the industry distribution chart, Sino Biopharmaceutical ranks #86 out of 960 companies in the Biotechnology industry, placing it in the top 9%.
Is Sino Biopharmaceutical's FCF Margin % too high?
Sino Biopharmaceutical's current FCF Margin % of 32.96% is 107% above median its 10-year median of 15.90. Over the past 10 years, this metric has ranged from a low of 12.93 to a high of 23.92. Based on the distribution chart, Sino Biopharmaceutical ranks #86 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #86 out of 960 companies for FCF Margin %. This places Sino Biopharmaceutical in the top 9% of its industry — outperforming the majority of peers. Historically, Sino Biopharmaceutical's own FCF Margin % has ranged from 12.93 to 23.92 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current FCF Margin % is 32.96%, which is 107% above median its own 10-year median of 15.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.68, compared to a current price of $0.60 — trading 11.5% below its estimated fair value. The current FCF Margin % is 32.96%, which is 107% above median its 10-year median of 15.90. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current FCF Margin % is 32.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.60 is trading 11.5% below its estimated GF Value™ of $0.68.
GuruFocus considers Sino Biopharmaceutical to be Modestly Undervalued.
Key valuation signals for SBMFF:
FCF Margin %: 32.96% (107% above median its 10-year median of 15.90)
GF Value™: $0.68 vs. price of $0.60 (11.5% below fair value)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score
Get the complete analysis for SBMFF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
